【摘要】 目的:探讨恩度肝动脉灌注联合介入化疗栓塞治疗中晚期肝癌的疗效及安全性。方法:选取30例中晚期肝癌患者入组研究,均给予恩度肝动脉灌注联合介入化疗栓塞治疗,同时选取30例中晚期肝癌患者作为对照组,仅行介入化疗栓塞治疗。于1～2个治疗周期后比较RECIST疗效,甲胎蛋白转阴率及生活质量评分,同时比较治疗副作用。结果:实验组30例患者中29例可评价疗效。实验组治疗后K氏评分显著升高(80.39±8.37Vs73.93±9.22,P=0.002);恩度治疗组的治疗有效率及甲胎蛋白转阴率显著高于对照组(P=0.021,P=0.046)。治疗副作用轻微。结论:采用恩度肝动脉灌注联合介入化疗栓塞治疗中晚期肝癌,患者生活质量及近期疗效提升明显,甲胎蛋白转阴率亦有明显改善,而治疗相关副作用不大,值得临床推广及进一步研究。更多还原

【Abstract】 Objective: To study the effects of intrahepatic arterial infusion of rh-endostatin (YH-16, Endostar) combined with transcatheter arterial chemoembolization (TACE) for treatment of advanced hepatocellular carcinoma. Methods: Thirty patients with advanced hepatocellular carcinoma who underwent intrahepatic arterial infusion of Endostar combined with TACE were enrolled in the study. The effects were evaluated after 1~2 cycles according to response evaluation criteria in solid tumors (RECIST) and the value of AFP was observed. Quality of life was assessed according to Karnofsky scoring. Results: Twenty-nine out of the 30 cases were evaluable. Karnofsky scores were significantly increased after the treatment (80.39±8.37 vs. 73.93±9.22, P=0.002). Compared with the control group, the overall response rate (CR and PR) and the rate of reversion to normal AFP expression were higher in the group treated with Endostar combined with TACE (P=0.021, P=0.046). No obvious adverse effects were observed. Conclusion: With few adverse effects, trancatheter arterial infusion of Endostar combined with TACE can improve the quality of life for patients with advanced hepatocellular carcinoma, and it can increase the rate of reversion to negative AFP expression. This treatment is worthy of clinical generalization and further clinical observation.更多还原